Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 21/4/2017
SIETES contiene 91761 citas

 1 a 20 de 63 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
2. Cita con resumen
3. Cita con resumen
Anónimo. GAO finds gaps In FDA’s drug-tracking system. DIA Daily 2016:15 de enero. [Ref.ID 99971]
4. Cita con resumen
Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf 2015;38:601-10. [Ref.ID 99852]
5. Cita con resumen
Anónimo. What next for the malaria RTS,S vaccine candidate?. Lancet 2015;386:1708. [Ref.ID 99666]
6. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
7. Cita con resumen
Dyer O. Drug maker must restart obesity drug study after releasing early data. BMJ 2015;350:h2844. [Ref.ID 99103]
8. Cita con resumen
Herman O. FDA advisers vote to keep black-box warning on Chantix. Journal Watch 2014:20 de octubre. [Ref.ID 98122]
9. Cita con resumen
Anónimo. Xolair (omalizumab): drug safety communication - Slightly elevated risk of cardiovascular and cerebrovascular serious adverse events. FDA U.S. Food and Drug Administration 2014:26 de septiembre. [Ref.ID 97997]
10. Cita con resumen
Anónimo. FDA approves naloxegol for opioid-induced constipation. DIA Daily 2014:17 de septiembre. [Ref.ID 97910]
13. Cita con resumen
Toussaint B. EU clinical trial regulation. Lancet 2013;381:1719-20. [Ref.ID 95444]
15. Cita con resumen
Duijnhoven RG, Straus SMJM, Raine JM, de Boer A, Hoes AW, De Bruin ML. Number of patients studied prior to approval of new medicines: database analysis. PLOS Medicine 2013;10:1. [Ref.ID 95146]
16.Tiene citas relacionadas Cita con resumen
Anónimo. My experience in the drug industry. BMJ 2012;344:28. [Ref.ID 93249]
17.Tiene citas relacionadas Cita con resumen
Gale E. Post-marketing studies of new insulins: science or sales?. BMJ 2012;344:24-7. [Ref.ID 93248]
Qato DM, Alexander GC. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. JAMA 2011;306:1595-6. [Ref.ID 91546]
19.Enlace a cita original
Blake KV, Prilla S, Accadebled S, Guimier M, Biscaro M, Persson I, Arlett P, Blackbum S, Fitt H. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf 2011;20:1021-9. [Ref.ID 91521]
20. Cita con resumen
Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA 2010;304:2172-3. [Ref.ID 89668]
Seleccionar todas
 1 a 20 de 63 siguiente >>